Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a steady uptake in the coming quarters. Interestingly, given the strong launch of Tepezza, management has upgraded the FY20 targets marginally. Note that the R&D pipeline has progressed quite well ytd – positive top-line data in amyloidosis and cervical cancer space – and this bodes well
13 Aug 2020
Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
13 Aug 2020 -
Author:
Sumit Sayal -
Pages:
3
Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a steady uptake in the coming quarters. Interestingly, given the strong launch of Tepezza, management has upgraded the FY20 targets marginally. Note that the R&D pipeline has progressed quite well ytd – positive top-line data in amyloidosis and cervical cancer space – and this bodes well